Boedeker Carsten C, Erlic Zoran, Richard Stéphane, Kontny Udo, Gimenez-Roqueplo Anne-Paule, Cascon Alberto, Robledo Mercedes, de Campos José M, van Nederveen Francien H, de Krijger Ronald R, Burnichon Nelly, Gaal José, Walter Martin A, Reschke Kirsten, Wiech Thorsten, Weber Johannes, Rückauer Klaus, Plouin Pierre Francois, Darrouzet Vincent, Giraud Sophie, Eng Charis, Neumann Hartmut P H
Department of Otorhinolaryngology, Albert-Ludwigs-University, Freiburg D-79106, Germany.
J Clin Endocrinol Metab. 2009 Jun;94(6):1938-44. doi: 10.1210/jc.2009-0354. Epub 2009 Mar 31.
Head and neck paragangliomas (HNPs) occur as sporadic or familial entities, the latter mostly in association with germline mutations of the SDHB, SDHC, or SDHD (SDHx) genes. Heritable non-SDHx HNP might occur in von Hippel-Lindau disease (VHL, VHL gene), multiple endocrine neoplasia type 2 (MEN2, RET gene), and neurofibromatosis type 1 (NF1, NF1 gene). Reports of non-SDHx HNP presentations are scarce and guidance for genetic testing nonexistent.
An international consortium registered patients with HNPs and performed mutation analyses of the SDHx, VHL, and RET genes. Those with SDHx germline mutations were excluded for purposes of this study. Personal and family histories were evaluated for paraganglial tumors, for the major tumor manifestations, and for family history of VHL, MEN2, or NF1.
Twelve patients were found to have hereditary non-SDHx HNPs of a total of 809 HNP and 2084 VHL registrants, 11 in the setting of germline VHL mutations and one of a RET mutation. The prevalence of hereditary HNP is five in 1000 VHL patients and nine in 1000 non-SDHx HNP patients. Comprehensive literature review revealed previous reports of HNPs in five VHL, two MEN2, and one NF1 patient. Overall, 11 here presented HNP cases, and four previously reported VHL-HNPs had lesions characteristic for VHL and/or a positive family history for VHL.
Our observations provide evidence that molecular genetic testing for VHL or RET germline mutations in patients with HNP should be done only if personal and/or family history shows evidence for one of these syndromes.
头颈部副神经节瘤(HNPs)可散发或呈家族性发病,后者大多与SDHB、SDHC或SDHD(SDHx)基因的种系突变有关。遗传性非SDHx HNP可能发生于冯·希佩尔-林道病(VHL,VHL基因)、2型多发性内分泌肿瘤(MEN2,RET基因)和1型神经纤维瘤病(NF1,NF1基因)。非SDHx HNP临床表现的报道稀少,且缺乏基因检测的指导。
一个国际联盟登记了HNPs患者,并对SDHx、VHL和RET基因进行了突变分析。本研究排除了有SDHx种系突变的患者。评估了患者个人及家族史中的副神经节瘤、主要肿瘤表现以及VHL、MEN2或NF1家族史。
在总共809例HNP和2084例VHL登记患者中,发现12例患者患有遗传性非SDHx HNP,其中11例存在VHL种系突变,1例存在RET突变。遗传性HNP在1000例VHL患者中的患病率为5例,在1000例非SDHx HNP患者中的患病率为9例。全面的文献综述显示,之前有5例VHL、2例MEN2和1例NF1患者发生HNP的报道。总体而言,本研究中有11例HNP病例,之前报道的4例VHL-HNP有VHL特征性病变和/或VHL阳性家族史。
我们的观察结果表明,仅当个人和/或家族史显示有这些综合征之一的证据时,才应对HNP患者进行VHL或RET种系突变的分子遗传学检测。